$PFSA

HRT FINANCIAL LP purchased $10K of PFSA

HRT FINANCIAL LP purchased 9,874 shares of Profusa, Inc. (PFSA) at an average of $1.05 ($1.01–$1.05) across 2 trades over 2026-07-30 to 2026-07-31.

Original reporting
SEC EDGAR · HRT FINANCIAL LP
Published Aug 3, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:16 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PFSA
Bullish
medium confidence
Mentioned
$PFSA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PFSABullishLow
01

Why it matters

The newest fact is the disclosed open-market purchase amount, price range, and resulting share count (93,745 shares after the trades).

02

Market read

Traders may treat the purchase as a small sentiment input, but it is unlikely to drive a durable repricing without accompanying fundamentals.

03

What to watch

The filing does not disclose intent, timing rationale, or whether the buyer’s stake changes are part of a larger accumulation program; follow-through would require additional filings or corporate updates.

Relevance 4/10Novelty 5/10Timing: filed Aug 3, 2026, covering trades on Jul 30-31

Background

This is an SEC Form 4 insider transaction disclosure for Profusa, Inc. (PFSA), reported by HRT Financial LP as a 10% owner.

Company-level read

Ticker impact

$PFSABullishMedium confidence
Context

Profusa, Inc. (PFSA) disclosed an insider Form 4 showing HRT Financial LP bought 9,874 shares at about $1.0457 average across two trades.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than earnings or guidance-driven.

Evidence & confidence

Form 4 purchases are primary-source but typically do not change valuation unless tied to a broader corporate event; the article provides size, price range, and post-transaction holdings only.

Market effects

No sector-wide implications; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

A 10% owner purchase can be routine liquidity or portfolio rebalancing, especially without a 10b5-1 plan and with small-dollar per-share pricing.

Key entities

  • Profusa, Inc.

    Company subject of the Form 4 insider transaction disclosure.

  • HRT Financial LP

    Reported as a 10% owner and buyer in the Form 4.

Related articles

$MRNAMed

Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

$PFSAMedAI 8/10

PFSA Stock Falls 19% Amid Diagnostics Acquisition News

Profusa (PFSA) said it signed a non-binding term sheet to acquire a privately held commercial diagnostics and toxicology testing company. The target estimates 2025 net revenues of about $111 million. Profusa would issue shares equal to 19.99% plus non-voting convertible preferred stock, subject to approval, and expects about $7 million financing via convertible notes. PFSA shares fell sharply after the news.